CARY, N.C., May 10 (UPI) -- NephroGenex said Wednesday it acquired commercial rights to BioStratum's Pyridorin, a potential diabetic neuropathy treatment.
NephroGenex also said it entered into a licensing agreement with Vanderbilt University in Nashville that covers the use of Pyridorin as a treatment for acute renal failure.
NephroGenex did not disclose the financial details of either deal.
The company said it is recruiting diabetic nephropathy patients for phase 3 trials of Pyridorin, and it also plans to initiate phase 2a and 2b trials of the compound for acute renal failure.
As part of the BioStratum deal, NephroGenex also obtained rights to the second-generation compound BST 605, which has been studied in preclinical and toxicity tests and appears to offer improved potency over Pyridorin.
Under the terms of the Vanderbilt deal, NephroGenex gained exclusive commercial rights to advances by researchers at the university's School of Medicine that indicate that Pyridorin scavenges reactive oxygen species and toxic carbonyl compounds that may contribute to the high mortality rates in acute-renal-failure patients.
